Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI   US6295191091

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Operates as an anti-infective drug development company

Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases.

The Company currently has two Phase 2 clinical-stage product candidates in development: laninamivir octanoate, a long-acting neuraminidase inhibitor that the Company is developing for the treatment of influenza A and B infections under an investigational new drug application (IND) in the United States through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that is designed to provide up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus (HRV).

In addition to these clinical-stage programs, the Company has a preclinical program focused on developing treatments for respiratory syncytial virus (RSV).

Biota Pharmaceuticals was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
Managers
NameAgeSinceTitle
Joseph M. Patti, PhD492012President, Chief Executive Officer & Director
Russell H. Plumb MBA, CPA542012Executive Chairman, CFO, Secretary & Treasurer
John Nicholas Lambert, PhD--Vice President-Product Development & Operations
Anna Novotney-Barry-2013Vice President-Clinical Development
Simon P. Tucker, PhD--Vice President-Research & Business Development
James Charles Fox, PhD622012Lead Independent Director
Geoffrey F. Cox, PhD702012Independent Non-Executive Director
Anne M. VanLent662013Independent Non-Executive Director
Michael R. Dougherty562013Independent Non-Executive Director
John P. Richard, MBA562013Independent Non-Executive Director
Shareholders
NameShares%
East Hill Management Co. LLC 2,940,289 8.38%
Broadfin Capital LLC 2,611,711 7.44%
JPMorgan Asset Management (UK) Ltd. 2,275,610 6.48%
Baker Bros. Advisors LP 1,106,910 3.15%
Hunter Hall Investment Management Ltd. 1,008,939 2.87%
Visium Asset Management LP 600,000 1.71%
BlackRock Advisors LLC 599,894 1.71%
BlackRock Fund Advisors 493,966 1.41%
BVF Partners LP 435,900 1.24%
Fidelity Management & Research Co. 414,979 1.18%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
ACTELION LTD
SHANGHAI RAAS BLO..
-
MEDIVATION INC
INTERCEPT PHARMAC..
JUNO THERAPEUTICS..
-
RECEPTOS INC
GENMAB A/S
HUALAN BIOLOGICAL..
BEIJING SL PHARMA..
BLUEBIRD BIO INC
AGIOS PHARMACEUTI..
NEUROCRINE BIOSCI..
TONGHUA DONGBAO P..
CLOVIS ONCOLOGY I..
KITE PHARMA INC
CHINA BIOLOGIC PR..
DYAX CORP.
TESARO INC
AUSPEX PHARMACEUT..
-
MANNKIND CORPORAT..
Sector Biotechnology & Medical Research
Biota Pharmaceuticals Inc : Connections
Phase4 Partners Ltd.
Shire ViroPharma, Inc.
AMV Advisors
Lakewood-Amedex, Inc.
Beacon Street Advisors LLC
AxoTect, Inc.
Gallus Biopharmaceuticals LLC
Altiris Therapeutics, Inc.
Alphavax, Inc.
Altherx, Inc.
International AIDS Vaccine Initiative, Inc.
Cempra Pharmaceuticals, Inc.
Altitude Aerospace Interiors Ltd.
TTP Group Plc
Technology Partnership Plc
Zygogen LLC
Multiple Sclerosis Research Australia Ltd.
Georgia Venture Partners LLC
Company contact information
Biota Pharmaceuticals, Inc.
2500 Northwinds Parkway
Suite 100
Alpharetta, GA 30009

Phone : +1.678.221.3343
Web : www.biotapharma.com
© 2015 People , Fundamentals and Ownership   
Dynamic quotes  
ON
| OFF